This trial is registered with the Dutch trial registry that has been offline for over a year and hasn’t been registered in any other database. We will update this record once it becomes available. All data are estimates.
Topic Healthy Subjects
Compound Psilocybin
2C-X
Country Netherlands
Visit trial
Status
Completed
Results Published
Yes
Start date
01 January 2022
End date
01 January 2023
Phase
Not Applicable
Design
Open
Type
Interventional
Generation
First
Participants
22
Sex
All
Age
18- 65
Therapy
No
Trial Details
This trial is registered with the Dutch trial registry that has been offline for over a year and hasn't been registered in any other database. We will update this record once it becomes available.Trial Number NL8813
Sponsors & Collaborators
Maastricht UniversityMaastricht University is host to the psychopharmacology department (Psychopharmacology in Maastricht) where various researchers are investigating the effects of psychedelics.
Papers
Assessment of the acute effects of 2C-B vs psilocybin on subjective experience, mood and cognitionThis double-blind study (n=22) compares the effect of 2C-B (20mg) and psilocybin (15mg). It finds that 2C-B elicited alterations in consciousness of a psychedelic nature but with a shorter duration of self-reported effects than psilocybin. The study categorised 2C-B (at least at that dose) as a subjectively "lighter" psychedelic.
Psilocybin and 4-Bromo-2,5-Dimethoxyphenethylamine (2C-B) at Encoding Distort Episodic Familiarity
This re-analysis of an RCT study (n=20) tested the acute effects of psilocybin and 2C-B on the encoding of emotional episodic memories. The study finds that both psychedelics impair estimates of recollection and familiarity, increase familiarity-based false alarms for emotional stimuli, and affect metamemory, indicating a common neurocognitive mechanism across these drugs.